Contribution of major histocompatibility complex class II immunostaining in distinguishing idiopathic inflammatory myopathy subgroups : A histopathological cohort study

Article Article scientifique Article Contribution of major histocompatibility complex class II immunostaining in distinguishing idiopathic inflammatory myopathy subgroups : A histopathological cohort study eng 2024-09-16 author Lessard Lola E R 0000-0002-3141-0227 Service d'Electroneuromyographie et de pathologies neuromusculaires, Hôpital Neurologique, GHE, Hospices Civils de Lyon, Lyon, France.,Institut NeuroMyoGène, Unité Physiopathologie et Génétique du Neurone et du Muscle, CNRS UMR 5261, Inserm U1315, Université Claude Bernard Lyon 1, Lyon, France. author Robert Marie 0000-0002-1374-6210 Service de Médecine interne et immunologie clinique, Centre Hospitalier Universitaire Édouard Herriot, Hospices Civils de Lyon, Lyon, France. author Fenouil Tanguy 0000-0002-2747-763X Institut de Pathologie Multisite des Hospices Civils de Lyon-Site Est, GHE, Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Lyon, France. author Mounier Rémi Institut NeuroMyoGène, Unité Physiopathologie et Génétique du Neurone et du Muscle, CNRS UMR 5261, Inserm U1315, Université Claude Bernard Lyon 1, Lyon, France. author Landel Véréna 0000-0002-3815-2048 Direction de la Recherche en Santé, Hospices Civils de Lyon, Lyon, France. author Carlesimo Marie 0009-0005-7587-1489 Institut de Pathologie Multisite des Hospices Civils de Lyon-Site Est, GHE, Hospices Civils de Lyon, Lyon, France. author Hot Arnaud Service de Médecine interne et immunologie clinique, Centre Hospitalier Universitaire Édouard Herriot, Hospices Civils de Lyon, Lyon, France. author Chazaud Bénédicte 0000-0002-1262-502X Institut NeuroMyoGène, Unité Physiopathologie et Génétique du Neurone et du Muscle, CNRS UMR 5261, Inserm U1315, Université Claude Bernard Lyon 1, Lyon, France. author Laumonier Thomas 0000-0002-8662-2972 Laboratoire "Cell Therapy & Musculoskeletal Disorders", Département de Chirurgie Orthopédique, Hôpital Universitaire et Faculté de Médecine, Genève, Switzerland. 135589 Département de chirurgie (CHIRU) author Streichenberger Nathalie 0000-0001-8665-1709 Institut NeuroMyoGène, Unité Physiopathologie et Génétique du Neurone et du Muscle, CNRS UMR 5261, Inserm U1315, Université Claude Bernard Lyon 1, Lyon, France.,Institut de Pathologie Multisite des Hospices Civils de Lyon-Site Est, GHE, Hospices Civils de Lyon, Lyon, France. author Gallay Laure 0000-0002-7020-1954 Service de Médecine interne et immunologie clinique, Centre Hospitalier Universitaire Édouard Herriot, Hospices Civils de Lyon, Lyon, France.,Laboratoire "Cell Therapy & Musculoskeletal Disorders", Département de Chirurgie Orthopédique, Hôpital Universitaire et Faculté de Médecine, Genève, Switzerland. 978054 nlae098 10.1093/jnen/nlae098 39283714 0022-3069 https://academic.oup.com/jnen/advance-article/doi/10.1093/jnen/nlae098/7758650 <p>Idiopathic inflammatory myopathies (IIM) are rare, acquired muscle diseases; their diagnosis of is based on clinical, serological, and histological criteria. MHC-I-positive immunostaining, although non-specific, is used as a marker for IIM diagnosis; however, the significance of major histocompatibility complex (MHC)-II immunostaining in IIM remains debated. We investigated patterns of MHC-II immunostaining in myofibers and capillaries in muscle biopsies from 103 patients with dermatomyositis ([DM], n = 31), inclusion body myositis ([IBM], n = 24), anti-synthetase syndrome ([ASyS], n = 10), immune-mediated necrotizing myopathy ([IMNM], n = 18), or overlap myositis ([OM], n = 20). MHC-II immunostaining of myofibers was abnormal in 63/103 of patients (61%) but the patterns differed according to the IIM subgroup. They were diffuse in IBM (96%), negative in IMNM (83%), perifascicular in ASyS (70%), negative (61%) or perifascicular (32%) in DM, and either clustered (40%), perifascicular (30%), or diffuse heterogeneous (15%) in OM. Capillary MHC-II immunostaining also identified quantitative (capillary dropout, n = 47/88, 53%) and qualitative abnormalities, that is, architectural abnormalities, including dilated and leaky capillaries, (n = 79/98, 81%) in all IIM subgroups. Thus, MHC-II myofiber expression patterns allow distinguishing among IIM subgroups. We suggest the addition of MHC-II immunostaining to routine histological panels for IIM diagnosis.</p> Capillary Idiopathic inflammatory myopathies Major histocompatibility complex-II Muscle biopsy Myofiber Dewey 617 57 Département de chirurgie 222 false 955 Mécanismes physiopathologiques de l'arthrose 960 Journal of neuropathology and experimental neurology 37e8a28a-4006-47ec-a649-490e2b988a0c Article (Published version) Public Article_scientifique_from_crossref.pdf 10192317 application/pdf CC BY-4.0 fa2b3e1eacc7f6fa7930a21f48e548f1eac78f4f9750558e97e98fc04a08bc48 f4d68c0e-8132-4abb-b5f8-8b03d513e8d1 Supplemental data Public nlae098_supplementary_data.zip 1375203 application/zip 1c6dd106175fdef415fbade6307075e881069fa521e2eef868d6cc135059314a openAccess Faculté de médecine / Section de médecine clinique / Département de chirurgie

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Contribution of major histocompatibility complex class II immunostaining in distinguishing idiopathic inflammatory myopathy subgroups : A histopathological cohort study	Journal of neuropathology and experimental neurology			2024	81	99

Archive ouverte UNIGE

Gallay, Laure